NanoCarrier Co., Ltd. (4571) AI Stock Analysis

• Market Cap: €14.97B
• Dividend Yield: N/A
• Average Volume (3M): 4.15M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: 51.72%
• EPS Growth: -34.93%
• Country: JP
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.85
• Shares Outstanding: 71,981,760
• 10 Day Avg. Volume: 11,552,300
• 30 Day Avg. Volume: 4,146,670
• PEG Ratio: -1.80
• Price to Book (P/B): 3.71
• Price to Sales (P/S): 93.58
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: ―

NanoCarrier Co., Ltd. faces significant financial challenges, with declining revenues and negative cash flows. While the company's balance sheet shows a strong equity position, operational and profitability issues are concerning. Technical analysis indicates a bearish trend, and the negative P/E ratio reflects ongoing financial struggles. These factors result in a low overall stock score, reflecting the company's current difficulties and uncertain outlook.

NanoCarrier Co., Ltd. Business Overview & Revenue Model

Company Description

NanoCarrier Co., Ltd. is a Japanese biopharmaceutical company that specializes in the development and commercialization of innovative nanotechnology-based drug delivery systems. The company focuses on creating highly effective and targeted treatments for cancer and other severe diseases through its proprietary micellar nanoparticle technology. NanoCarrier is committed to advancing healthcare by improving the efficacy and safety profiles of therapeutic agents.

How the Company Makes Money

NanoCarrier Co., Ltd. generates revenue primarily through the development, licensing, and commercialization of its proprietary drug delivery systems. The company collaborates with pharmaceutical companies to co-develop drugs using its nanotechnology platforms, earning revenues from licensing fees, milestone payments, and royalties on sales of co-developed products. Additionally, NanoCarrier may receive funding from government grants or private investments to support its research and development activities. Strategic partnerships and collaborations with other biotech and pharmaceutical companies also play a significant role in enhancing its market reach and financial performance.

NanoCarrier Co., Ltd. Financial Statement Overview

Summary

NanoCarrier Co., Ltd. is experiencing financial difficulties with declining revenues and substantial operational losses. Despite a strong equity position and conservative debt management, the persistent lack of profitability and negative cash flows raise concerns about its long-term financial sustainability.

Income Statement

NanoCarrier Co., Ltd. has been experiencing declining revenue over the years, with the TTM (Trailing-Twelve-Months) revenue dropping significantly from previous periods. The company has negative profit margins, indicating it is not profitable. Both EBIT and EBITDA margins are deeply negative, reflecting operational challenges.

Balance Sheet

The balance sheet shows a relatively strong equity position, with a low debt-to-equity ratio, indicating conservative leverage. However, the company's equity is decreasing over time. The equity ratio is solid, suggesting a strong reliance on equity financing, which is positive in managing financial risk.

Cash Flow

Cash flow analysis reveals significant challenges, with consistently negative free cash flow indicating cash outflows exceeding inflows. The company has not generated positive operating cash flow recently, which could threaten liquidity if this continues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	116.10M	108.52M	135.51M	202.19M	264.03M	313.26M
Gross Profit	84.46M	78.17M	110.96M	159.60M	222.74M	274.89M
EBITDA	-776.70M	-832.57M	-863.00M	-1.25B	-2.06B	-1.30B
Net Income	-879.96M	-835.38M	-780.00M	-1.31B	-1.88B	-2.84B
Balance Sheet
Total Assets	3.93B	4.00B	5.07B	5.78B	7.14B	7.82B
Cash, Cash Equivalents and Short-Term Investments	3.40B	3.51B	4.28B	4.44B	5.95B	6.40B
Total Debt	540.24M	540.24M	1.11B	1.11B	1.15B	0.00
Total Liabilities	1.28B	1.26B	1.65B	1.53B	1.57B	321.00M
Stockholders Equity	2.66B	2.74B	3.42B	4.25B	5.57B	7.50B
Cash Flow
Free Cash Flow	0.00	0.00	-585.08M	-1.09B	-1.76B	-1.25B
Operating Cash Flow	0.00	-401.62M	-585.08M	-1.09B	-1.75B	-1.25B
Investing Cash Flow	0.00	587.53M	793.01M	1.21B	-244.13M	-871.69M
Financing Cash Flow	0.00	-568.77M	3.73M	32.20M	1.15B	-11.46M

NanoCarrier Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 184.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4571, the sentiment is Positive. The current price of 184 is above the 20-day moving average (MA) of 152.60, above the 50-day MA of 151.46, and above the 200-day MA of 142.03, indicating a bullish trend. The MACD of 14.52 indicates Negative momentum. The RSI at 58.20 is Neutral, neither overbought nor oversold. The STOCH value of 68.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4571.

NanoCarrier Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4584	55 Neutral	¥12.14B	35.84	―	―	120.34%	―
4588	53 Neutral	¥19.75B	―	―	―	-9.04%	2.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4583	48 Neutral	¥9.19B	―	―	―	30.92%	26.00%
2370	45 Neutral	¥9.00B	―	―	―	-0.97%	1.19%
4594	45 Neutral	¥7.57B	―	―	―	1254.76%	33.94%
4571	40 Underperform	€14.97B	―	-31.29%	―	51.72%	-34.93%